Literature DB >> 23208314

Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA-identical sibling donors in AML and MDS with <10% BM blasts: a report from EBMT.

R Martino1, L de Wreede, M Fiocco, A van Biezen, P A von dem Borne, R-M Hamladji, L Volin, M Bornhäuser, M Robin, V Rocha, T de Witte, N Kröger, M Mohty.   

Abstract

In this multicenter retrospective study, the long-term outcomes of 878 adults with AML and refractory anemia with excess blasts (RAEB) with BM blasts <10% who underwent transplantation with an HLA-identical sibling donor between 1998 and 2004 were analyzed according to four regimens of conditioning intensity: reduced-intensity conditioning (RIC) (either intermediate RIC (IntermRIC) or non-myeloablative (NMA) RIC), and myeloablative conditioning (MC) in 718 patients (either conventional MC or hyperintense MC. In multivariate cox analysis, patients undergoing NMA transplantation had lower non-relapse mortality risk in the first 100 days after transplantation (P<0.01), but a higher risk beyond day +100 (P=0.02), as well as higher relapse incidence in the first 12 months (P<0.01), but the risk was similar in all groups beyond 12 months. The probabilities of PFS and OS up to 7 years were significantly lower only in the NMA subgroup (P0.01 for both). The 7-year OS was 53%, 29%, 56% and 51%, respectively. Our data suggest that prospective studies comparing RIC regimens (especially IntermRIC) with MC are appropriate in patients with AML and RAEB who are in a non-advanced disease status.

Entities:  

Mesh:

Year:  2012        PMID: 23208314     DOI: 10.1038/bmt.2012.236

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  38 in total

Review 1.  Risk factors for relapse after allogeneic transplantation in acute myeloid leukemia.

Authors:  Gert J Ossenkoppele; Jeroen J W M Janssen; Arjan A van de Loosdrecht
Journal:  Haematologica       Date:  2016-01       Impact factor: 9.941

2.  Long-term outcomes of allogeneic hematopoietic cell transplantation with intensified myeloablative conditioning for refractory myeloid malignancy.

Authors:  N Kawashima; Y Inamoto; T Sato; M Nakashima; Y Kagaya; K Watakabe; A Seto; N Fukushima; S Kurahashi; Y Ozawa; K Miyamura
Journal:  Bone Marrow Transplant       Date:  2016-02-15       Impact factor: 5.483

3.  Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis.

Authors:  Tania Jain; Katie L Kunze; M'hamed Temkit; Daniel K Partain; Mrinal S Patnaik; James L Slack; Nandita Khera; William J Hogan; Vivek Roy; Pierre Noel; Jose F Leis; Lisa Z Sproat; Veena Fauble; Ruben A Mesa; Jeanne Palmer
Journal:  Bone Marrow Transplant       Date:  2018-05-24       Impact factor: 5.483

4.  Conditioning intensity in middle-aged patients with AML in first CR: no advantage for myeloablative regimens irrespective of the risk group-an observational analysis by the Acute Leukemia Working Party of the EBMT.

Authors:  J R Passweg; M Labopin; J Cornelissen; L Volin; G Socié; A Huynh; R Tabrizi; D Wu; C Craddock; N Schaap; J Kuball; P Chevallier; J Y Cahn; D Blaise; A Ghavamzadeh; K Bilger; F Ciceri; C Schmid; S Giebel; A Nagler; M Mohty
Journal:  Bone Marrow Transplant       Date:  2015-06-01       Impact factor: 5.483

5.  Differences in community and academic practice patterns for newly diagnosed myelodysplastic syndromes (MDS) patients.

Authors:  Daniel F Pease; Julie A Ross; Jenny N Poynter; Phuong L Nguyen; Betsy Hirsch; Adina Cioc; Michelle A Roesler; Erica D Warlick
Journal:  Cancer Epidemiol       Date:  2015-02-18       Impact factor: 2.984

Review 6.  Reduced-intensity conditioned allogeneic SCT in adults with AML.

Authors:  R Reshef; D L Porter
Journal:  Bone Marrow Transplant       Date:  2015-03-02       Impact factor: 5.483

7.  Long-term follow-up of a retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic transplantation from matched related donors in myelodysplastic syndromes.

Authors:  R Martino; A Henseler; M van Lint; N Schaap; J Finke; D Beelen; S Vigouroux; E P Alessandrino; G J Mufti; J H Veelken; B Bruno; I Yakoub-Agha; L Volin; J Maertens; R Or; V Leblond; M Rovira; P Kalhs; A F Alvarez; A Vitek; J Sierra; E Wagner; M Robin; T de Witte; N Kröger
Journal:  Bone Marrow Transplant       Date:  2017-03-20       Impact factor: 5.483

8.  Reduced-toxicity conditioning prior to allogeneic stem cell transplantation improves outcome in patients with myeloid malignancies.

Authors:  Claire Oudin; Patrice Chevallier; Sabine Furst; Thierry Guillaume; Jean El Cheikh; Jacques Delaunay; Luca Castagna; Catherine Faucher; Angela Granata; Raynier Devillier; Christian Chabannon; Benjamin Esterni; Norbert Vey; Mohamad Mohty; Didier Blaise
Journal:  Haematologica       Date:  2014-08-01       Impact factor: 9.941

9.  A gentle ethical defence of homeopathy.

Authors:  David Levy; Ben Gadd; Ian Kerridge; Paul A Komesaroff
Journal:  J Bioeth Inq       Date:  2014-07-19       Impact factor: 1.352

10.  Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio.

Authors:  J Versluis; F E M In 't Hout; R Devillier; W L J van Putten; M G Manz; M-C Vekemans; M-C Legdeur; J R Passweg; J Maertens; J Kuball; B J Biemond; P J M Valk; B A van der Reijden; G Meloni; H C Schouten; E Vellenga; T Pabst; R Willemze; B Löwenberg; G Ossenkoppele; F Baron; G Huls; J J Cornelissen
Journal:  Leukemia       Date:  2016-06-24       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.